Precisio Biotix Therapeutics has entered a collaboration with Mayo Clinic, which will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections.   Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections. The Company’s key assets include: LysiThru, the Company’s high throughput screening, engineering, and AI system for creating best- or first-in-class novel l...